Want to see NRXP full AI Analyst Report?
NRX Pharmaceuticals (NRXP) Income Statement
NRX Pharmaceuticals Income Statement
Last quarter (Q2 2026), NRX Pharmaceuticals's total revenue was $1.10M. In Q2, NRX Pharmaceuticals's net income was $-16.52M. See NRX Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| $ 1.23M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 720.00K | $ -5.00K | $ -5.00K | $ -4.00K | $ -2.00K | |
| $ 16.94M | $ 19.70M | $ 27.58M | $ 44.33M | $ 95.20M | |
| Depreciation and Amortization | $ 143.00K | $ 5.00K | $ 5.00K | $ 4.00K | $ 2.00K |
| $ -27.81M | $ -24.04M | $ -30.02M | $ -39.75M | $ -93.04M | |
| $ -16.22M | $ -19.70M | $ -27.59M | $ -44.34M | $ -95.20M | |
| $ -12.40M | $ -5.42M | $ -2.56M | $ 4.58M | $ 2.14M | |
| $ -28.62M | $ -25.13M | $ -30.15M | $ -39.75M | $ -93.06M | |
| $ -28.62M | $ -25.13M | $ -30.15M | $ -39.75M | $ -93.06M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.34 | $ -2.39 | $ -3.98 | $ -0.60 | $ -7.44 |
| Diluted EPS | $ -1.34 | $ -2.39 | $ -3.98 | $ -0.60 | $ -7.44 |
| Weighted Average Shares Outstanding | 21.40M | 10.52M | 7.58M | 65.77M | 46.92M |
| Weighted Average Shares Outstanding (Diluted) | 21.40M | 10.52M | 7.58M | 65.77M | 46.92M |
Currency in USD
